Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;37(6):783-785.
doi: 10.1016/j.virs.2022.11.002. Epub 2022 Nov 7.

Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines

Anthony T Tan  1 , Joey Ming Er Lim  1 , Antonio Bertoletti  2
Affiliations

Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines

Anthony T Tan et al. Virol Sin. 2022 Dec.

Abstract

  1. •

    Viral lineages that escape antibodies have changed the landscape of the pandemic.

  2. •

    SARS-CoV-2 specific T cells effectively protect against disease development.

  3. •

    Vaccine efficacy should be evaluated by its ability to protect from severe disease.

  4. •

    Inactivated SARS-CoV-2 vaccine induces a multi-protein specific T cell response.

  5. •

    The superior breadth of the vaccine T cell response could be a protective asset.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Characteristics of spike mRNA and inactivated SARS-CoV-2 vaccine-induced T cell response. NP, nucleoprotein; Mem, membrane.
See this image and copyright information in PMC

References

    1. Bertoletti A., Le Bert N., Tan A.T. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity. 2022;55:1764–1778. - PMC - PubMed
    1. Cerqueira-Silva T., Katikireddi S.V., De Araujo Oliveira V., Flores-Ortiz R., Junior J.B., Paixao E.S., Robertson C., Penna G.O., Werneck G.L., Barreto M.L., Pearce N., Sheikh A., Barral-Netto M., Boaventura V.S. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Med. 2022;28:838–843. - PMC - PubMed
    1. Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., Nakao C., Rayaprolu V., Rawlings S.A., Peters B., Krammer F., Simon V., Saphire E.O., Smith D.M., Weiskopf D., Sette A., Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371 - PMC - PubMed
    1. Gao Y., Cai C., Grifoni A., Muller T.R., Niessl J., Olofsson A., Humbert M., Hansson L., Osterborg A., Bergman P., Chen P., Olsson A., Sandberg J.K., Weiskopf D., Price D.A., Ljunggren H.G., Karlsson A.C., Sette A., Aleman S., Buggert M. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 2022;28:472–476. - PMC - PubMed
    1. Heller K.N., Gurer C., Munz C. Virus-specific CD4+ T cells: ready for direct attack. J. Exp. Med. 2006;203:805–808. - PMC - PubMed

Publication types